Physician profile
Michael Baio
NPI 1376523795
$8,828.95
in general payments reported to CMS, 2019-2025
33 companies · $1,539 in 2025
The $1,539 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,258 · 2020: $972 · 2021: $1,193 · 2022: $1,398 · 2023: $1,085 · 2024: $1,384 · 2025: $1,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,008.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $935.47 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $914.74 | 2019-2025 | Ubrelvy, Synthroid |
| Bayer Healthcare Pharmaceuticals INC. | $710.42 | 2022-2025 | |
| Amarin Pharma, INC. | $615.67 | 2019-2022 | |
| Pfizer INC. | $611.98 | 2019-2025 | |
| Novo Nordisk INC | $586.00 | 2022-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $584.42 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $472.85 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Almatica Pharma LLC | $286.82 | 2021-2025 | Loreev Xr, Gralise |
| Astellas Pharma US INC | $280.16 | 2019-2024 | Veozah |
| Amgen INC. | $270.50 | 2019-2025 | Repatha, Evenity, Repatha |
| Kowa Pharmaceuticals America, INC. | $241.49 | 2019-2025 | Zoryve, Seglentis |
| Allergan, INC. | $237.18 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $208.84 | 2023 | Quviviq |
| Janssen Biotech, INC. | $203.20 | 2024-2025 | Tremfya |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $200.73 | 2020-2025 | Arexvy, Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $187.88 | 2024-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $164.90 | 2019-2023 | Dificid |
| Novartis Pharmaceuticals Corporation | $163.17 | 2019-2023 | |
| Eisai INC. | $159.92 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $141.57 | 2023-2024 | Voquezna |
| Exact Sciences Corporation | $140.50 | 2024-2025 | Cologuard Collection Kit |
| Seqirus USA INC | $139.30 | 2020-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.01 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.23 | 2019-2024 | Eohilia |
| Otsuka America Pharmaceutical, INC. | $50.35 | 2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $46.91 | 2025 | Unithroid |
| Radius Health, INC. | $44.55 | 2019-2020 | |
| Daiichi Sankyo INC. | $35.50 | 2022-2023 | Injectafer |
| Paratek Pharmaceuticals, INC. | $17.13 | 2023 | Nuzyra |
| Bausch Health US, LLC | $16.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.49 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Baio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.